Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | May 29, 2018 | May 30, 2018 |
| Revolution Healthcare Acquisition Corp.REVH · Entity 135631 | Director | March 17, 2021 | March 17, 2021 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director · Executive Chairman | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 270,198 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Purchase · Acquired 5,000 · Balance 270,198 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 31,644 |
Last balance in matching sequence
After 2026-05-11 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2026-05-11 · Conversion · Acquired 28,698 · Balance 28,698 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 3 · 2026-05-11 · Exercise / conversion · Acquired 2,963 · Balance 31,661 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 4 · 2026-05-11 · Tax withholding · Disposed 17 · Balance 31,644 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-11 · Conversion · Disposed 79,166 · Balance 0 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-11 · Conversion · Disposed 100,000 · Balance 0 F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-11 · Conversion · Disposed 96,002 · Balance 0 F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 626,220 |
Reported balance
After 2026-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-07 · Grant · Acquired 626,220 · Balance 626,220 F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
| Series D Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10 | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-11 · Exercise / conversion · Disposed 28,800 · Balance 0 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise.
F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
QUEST DIAGNOSTICS INC
Report date May 29, 2018 · Filed May 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2018-05-29 transaction · row 1
1 source rowRow 1 · 2018-05-29 · Sale · Disposed 1,644 · Balance 6,000 |
Revolution Healthcare Acquisition Corp.
Report date March 17, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table I · non-derivative | IndirectBy Racing Beach Ventures LLC | 7,500 |
Reported balance
Holding disclosure · report date 2021-03-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,500 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination. F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.
F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,797 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Tax withholding · Disposed 3,547 · Balance 34,797 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 440 |
Reported balance
Holding disclosure · report date 2026-02-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 440 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date March 24, 2006 · Filed March 28, 2006
Section 16 reporting ended · disclosed 2006-03-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 209,401 |
Ending reported balance
After 2006-03-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2006-03-24 · Tax withholding · Disposed 91,846 · Balance 309,401 Row 2 · 2006-03-24 · Disposition to issuer · Disposed 100,000 · Balance 209,401 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 635 |
Reported balance
Holding disclosure · report date 2006-03-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 635 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2019 Filed Nov 4, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 70,290 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · derivative · entry 9 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,290 Underlying: Common Stock · 70,290 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 26,532 | $200.06 | $5,307,991.92 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $200.06 (range $200.00 to $200.10). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 26,532 | $131.89 | $3,499,305.48 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 70,290 | $200.00 | $14,058,000.00 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 70,290 | $109.14 | $7,671,450.60 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,879 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · derivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,210 Underlying: Common Stock · 8,879 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 8,879 | $200.00 | $1,775,800.00 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 8,879 | $131.89 | $1,171,051.31 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,411 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · derivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,089 Underlying: Common Stock · 35,411 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 72,420 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · derivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,580 Underlying: Common Stock · 72,420 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 35,411 | $190.00 | $6,728,090.00 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 35,411 | $131.89 | $4,670,356.79 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 72,420 | $190.00 | $13,759,800.00 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 72,420 | $109.14 | $7,903,918.80 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options (Right to Buy) · Derivative | 56,030 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-19-038237 · doc4.xml · derivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,030 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,249 | $176.11 | $748,291.39 |
DisclosureSEC source: 0001209191-19-038237 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $176.11 (range $176.02 to $176.36). Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 51,781 | $175.33 | $9,078,762.73 |
DisclosureSEC source: 0001209191-19-038237 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,536 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $175.33 (range $175.00 to $176.00). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 56,030 | $77.31 | $4,331,679.30 |
DisclosureSEC source: 0001209191-19-038237 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2019 Filed May 28, 2019 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 113,432 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-19-033062 · doc4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,030 Underlying: Common Stock · 113,432 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| May 24, 2019 Filed May 28, 2019 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 113,432 | $175.10 | $19,861,943.20 |
DisclosureSEC source: 0001209191-19-033062 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $175.10 (range $175.00 to $175.71). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 24, 2019 Filed May 28, 2019 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 113,432 | $77.31 | $8,769,427.92 |
DisclosureSEC source: 0001209191-19-033062 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2019 Filed May 8, 2019 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,300 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-19-028221 · doc4.xml · derivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,462 Underlying: Common Stock · 2,300 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| May 06, 2019 Filed May 8, 2019 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,758 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-19-028221 · doc4.xml · derivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,762 Underlying: Common Stock · 30,758 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| May 06, 2019 Filed May 8, 2019 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleComomn Stock | 2,300 | $175.02 | $402,546.00 |
DisclosureSEC source: 0001209191-19-028221 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,195 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $175.02 (range $175.00 to $175.13). Read SEC document |
| May 06, 2019 Filed May 8, 2019 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,300 | $77.31 | $177,813.00 |
DisclosureSEC source: 0001209191-19-028221 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2019 Filed May 8, 2019 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30,758 | $175.01 | $5,382,957.58 |
DisclosureSEC source: 0001209191-19-028221 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,195 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $175.01 (range $175.00 to $175.13). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2019 Filed May 8, 2019 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 30,758 | $77.31 | $2,377,900.98 |
DisclosureSEC source: 0001209191-19-028221 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-19-027306 · doc4.xml · derivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,520 Underlying: Common Stock · 300 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,180 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-19-027306 · doc4.xml · derivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,820 Underlying: Common Stock · 10,180 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $175.04 | $52,512.00 |
DisclosureSEC source: 0001209191-19-027306 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,195 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $175.04 (range $175.00 to $175.12). Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 300 | $77.31 | $23,193.00 |
DisclosureSEC source: 0001209191-19-027306 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,180 | $175.08 | $1,782,314.40 |
DisclosureSEC source: 0001209191-19-027306 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,195 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $175.08 (range $175.00 to $175.49). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,180 | $77.31 | $787,015.80 |
DisclosureSEC source: 0001209191-19-027306 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $188.61 | $226,332.00 |
DisclosureSEC source: 0001209191-19-011999 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,195 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $188.61 (range $188.50 to $188.73). Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,700 | $187.43 | $506,061.00 |
DisclosureSEC source: 0001209191-19-011999 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,395 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $187.43 (range $187.17 to $188.09). Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17,097 | $186.80 | $3,193,719.60 |
DisclosureSEC source: 0001209191-19-011999 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,095 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $187.14 (range $186.16 to $187.14). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 412 | $181.80 | $74,901.60 |
DisclosureSEC source: 0001209191-19-009663 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,192 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $179.28 (range $178.47 to $179.47). F6 · price: Open market sales reported on this line occurred at a weighted average price of $181.80 (range $181.52 to $181.81). Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 48,651 | $180.81 | $8,796,587.31 |
DisclosureSEC source: 0001209191-19-009663 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,604 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $180.81 (range $180.48 to $181.45). Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 47,661 | $179.93 | $8,575,643.73 |
DisclosureSEC source: 0001209191-19-009663 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,255 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $179.93 (range $179.48 to $180.47). Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 14,707 | $179.28 | $2,636,670.96 |
DisclosureSEC source: 0001209191-19-009663 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,916 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $179.28 (range $178.47 to $179.47). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 72,647 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008582 · doc4.xml · derivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,647 Underlying: Common Stock · 72,647 shares Expires 2029-02-05 F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 28,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008582 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,623 F3 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 31,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008582 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,179 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 53,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008582 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,681 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/2/2016 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019 and the shares will vest on 2/10/2019. Read SEC document |
| February 05, 2019 Filed Feb 7, 2020 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 31,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007495 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,818 F3 · shares: Restricted stock unit award that will vest pursuant to his employment agreement upon Dr. Leiden's transition from CEO. Read SEC document |
| February 05, 2019 Filed Feb 7, 2020 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 28,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007495 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,356 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest in installments beginning on 02/24/2020. Read SEC document |
| February 05, 2019 Filed Feb 7, 2020 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 50,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007495 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,912 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $187.91 | $169,119.00 |
DisclosureSEC source: 0001209191-19-007764 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,865 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $187.91 (range $187.51 to $188.25). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,951 | $186.70 | $2,417,951.70 |
DisclosureSEC source: 0001209191-19-007764 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,765 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $186.70 (range $186.39 to $187.29). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17,099 | $186.10 | $3,182,123.90 |
DisclosureSEC source: 0001209191-19-007764 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,716 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $186.10 (range $185.55 to $186.38). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.